LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.

abstract：BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

journal_title：Thoracic cancer

authors： Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information o...

journal_title：Thoracic cancer

authors： Ming Z,Jiang M,Li W,Fan N,Deng W,Zhong Y,Zhang Y,Zhang Q,Yang S

更新日期：2014-11-01 00:00:00

abstract：:We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

journal_title：Thoracic cancer

authors： Matsukuma S,Obara K,Kono T,Takeo H,Sato K

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

journal_title：Thoracic cancer

authors： Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Next-generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy; however, little is known about the performance of the Oncomine Dx Target Test compared with conventional single gene tests for detecting EGFR mutations. The objective of this st...

journal_title：Thoracic cancer

authors： Sakaguchi T,Iketani A,Furuhashi K,Nakamura Y,Suzuki Y,Ito K,Fujiwara K,Nishii Y,Katsuta K,Taguchi O,Hataji O

更新日期：2020-12-12 00:00:00

abstract：:A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...

journal_title：Thoracic cancer

authors： Lee HJ,Seon HJ,Choi YD

更新日期：2018-01-01 00:00:00

abstract：:SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

journal_title：Thoracic cancer

authors： Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...

journal_title：Thoracic cancer

authors： Ai C,Ma G,Deng Y,Zheng Q,Gen Y,Li W,Li Y,Zu L,Zhou Q

更新日期：2020-03-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS:Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who re...

journal_title：Thoracic cancer

authors： Zhu Y,Fu L,Jing W,Guo D,Kong L,Yu J

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...

journal_title：Thoracic cancer

authors： Hayakawa D,Takahashi F,Mitsuishi Y,Tajima K,Hidayat M,Winardi W,Ihara H,Kanamori K,Matsumoto N,Asao T,Ko R,Shukuya T,Takamochi K,Hayashi T,Suehara Y,Takeda Nakamura I,Ueno T,Kohsaka S,Mano H,Takahashi K

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

journal_title：Thoracic cancer

authors： Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

更新日期：2019-09-01 00:00:00

abstract：:After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

journal_title：Thoracic cancer

authors： Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

更新日期：2017-07-01 00:00:00

abstract：:A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

journal_title：Thoracic cancer

authors： Wang H

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：:Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

journal_title：Thoracic cancer

authors： Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

journal_title：Thoracic cancer

authors： Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

更新日期：2015-07-01 00:00:00

abstract：:Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

journal_title：Thoracic cancer

authors： Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...

journal_title：Thoracic cancer

authors： Gil HI,Choe J,Jeong BH,Um SW,Jeon K,Hahn JY,Kim H,Kwon OJ,Chang YS,Lee K

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...

journal_title：Thoracic cancer

authors： Hu MM,Hu Y,Gao GK,Han Y,Shi GL,Li BL

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...

journal_title：Thoracic cancer

authors： Li S,Sun X,Miao S,Lu T,Wang Y,Liu J,Jiao W

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...

journal_title：Thoracic cancer

authors： Wang X,Jiang X,Li J,Wang J,Binang H,Shi S,Duan W,Zhao Y,Zhang Y

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

journal_title：Thoracic cancer

authors： Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

更新日期：2019-04-01 00:00:00

abstract：:Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...

journal_title：Thoracic cancer

authors： Wang H,Ke M,Li W,Wang Z,Li H,Cong M,Zeng Y,Chen L,Lai G,Xie B,Zhang N,Li W,Zhou H,Wang X,Lin D,Zhou Y,Zhang H,Li D,Song X,Wang J,Wu S,Tao M,Sha Z,Tan Q,Han X,Luo L,Ma H,Wang Z

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

journal_title：Thoracic cancer

authors： Hsia TC,Liang JA,Li CC,Chien CR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus...

journal_title：Thoracic cancer

authors： Shang B,Li J,Wang X,Li D,Liang B,Wang Y,Han X,Dou W,Chen G,Shang J,Jiang S

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

journal_title：Thoracic cancer

authors： Sang Y,Bo L,Gu H,Yang W,Chen Y

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

journal_title：Thoracic cancer

authors： Huang P,Ye B,Yang Y,Tantai JC,Zhao H

更新日期：2014-07-01 00:00:00

abstract：:Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

journal_title：Thoracic cancer

authors： Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

journal_title：Thoracic cancer

authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

更新日期：2020-10-01 00:00:00